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A B S T R A C T
Quantiﬁcation of the total amount of human DNA isolated from a forensic evidence item is crucial for
DNA normalization prior to short tandem repeat (STR) DNA analysis and a federal quality assurance
standard requirement. Previous commercial quantiﬁcation methods determine the total human DNA and
total human male DNA concentrations, but provide limited information about the condition of the DNA
sample. The PowerQuant1 System includes targets for quantiﬁcation of total human and total human
male DNA as well as targets for evaluating whether the human DNA is degraded and/or PCR inhibitors are
present in the sample. A developmental validation of the PowerQuant1 System was completed, following
SWGDAM Validation Guidelines, to evaluate the assay’s speciﬁcity, sensitivity, precision and accuracy, as
well as the ability to detect degraded DNA or PCR inhibitors. In addition to the total human DNA and total
human male DNA concentrations in a sample, data from the degradation target and internal PCR control
(IPC) provide a forensic DNA analyst meaningful information about the quality of the isolated human
DNA and the presence of PCR inhibitors in the sample that can be used to determine the most effective
workﬂow and assist downstream interpretation.
ã 2016 The Author(s). Published by Elsevier Ireland Ltd. All rights reserved.
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An evidentiary item collected from a crime scene may contain
non-human sources of DNA. After DNA is isolated from evidence, a
measurement of the amount of recovered human DNA is necessary
for normalization to the optimal mass for typing with a short
tandem repeat (STR) multiplex and compliance with FBI Quality
Assurance Standards [1].
Quantitative PCR (qPCR) is a sensitive method for DNA
quantiﬁcation and is compatible with multiplexing targets. qPCR
is routinely used to measure the concentration of total human and
total human male DNA [2–4]. The inclusion of an additional* Corresponding author.
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samples has also been used [5–9].
The PowerQuant1 System (Promega Corporation, Madison, WI)
combines multicopy quantiﬁcation for each target and an internal
PCR control (IPC) in one 5-dye qPCR assay to quantify total human
and human male DNA present in a sample and ascertain whether
PCR inhibitors and/or degraded human DNA are present. Hydroly-
sis probes are used for detection with an Applied Biosystems1
7500 Real-Time PCR System instrument [10]. The PowerQuant1
20X Primer/Probe/IPC Mix provided in the system contains the
primers, probes, internal PCR control (IPC) template and passive
reference dye. Also included in the system are the PowerQuant1
2X Master Mix and the PowerQuant1 Male gDNA Standard. The
PowerQuant1 2X Master Mix uses a hot-start chemistry for room
temperature reaction set-up and is designed for performance
comparable to newer STR systems [11,12]. The PowerQuant1Male
gDNA Standard consists of pooled genomic human male DNA and
is used to generate the standard curve for determining DNA
concentration in the samples..
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for the 84 base pair autosomal target quantify the total amount of
human DNA in a sample. This proprietary target is present at high
copy number for sensitivity, but exhibits low variation in the
human population for consistent total human DNA to total human
male DNA ratios ([Auto]/[Y]) [13].
The primers and hydrolysis probe (labeled with Quasar1 670/
BHQ1-2) for the degradation target are used to amplify and detect
a longer portion (294 bp) of the same proprietary locus as the
autosomal target. To eliminate any potential for ampliﬁcation
interference of one target by the other, the autosomal and
degradation amplicons are separated by several kilobases. The
larger degradation target is more likely to be affected by
degradation of the DNA template than the shorter autosomal
target. When DNA is degraded, the concentration of DNA detected
with the degradation target is less than the concentration detected
with the autosomal target. The ratio of the human DNA
concentration detected with the autosomal target relative to the
degradation target ([Auto]/[D]) may be used to evaluate DNA
degradation.
The Y primers and probes (labeled with Cal Fluor1 Gold 540/
BHQ1-1) target two different proprietary multicopy loci (81 bp
and 136 bp amplicons) speciﬁc to the Y chromosome and measure
the total amount of human male DNA in a sample. Targeting two
multicopy loci increases the sensitivity while minimizing the effect
that variation in copy number of one Y locus would have on the
overall Y quantiﬁcation result.
The primers and hydrolysis probe (labeled with TMR/BHQ1-2)
for the internal PCR control (IPC) are used to amplify and detect a
novel DNA template. The IPC’s quantiﬁcation cycle (Cq) provides
information about the presence of PCR inhibitors in a DNA sample
[2–9,14]. To increase susceptibility to PCR inhibitors relative to the
other targets in the PowerQuant1 System, including the 294 bp
degradation amplicon, the IPC is the longest amplicon (435 bp).
Developmental validation of the of the PowerQuant1 System
includes all of the studies required by the FBI Quality Assurance
Standards for Forensic DNA Testing Laboratories and the SWGDAM
Validation Guidelines for DNA Analysis Methods [1,15]. The results
demonstrate that the PowerQuant1 System is a sensitive and
reliable primate speciﬁc quantiﬁcation method capable of detect-
ing degraded DNA, as well as concentrations of commonly
encountered PCR inhibitors such as hematin, humic acid and
tannic acid that would have an effect on an STR proﬁle.
Concentrations of human DNA as low as 0.5 pg/mL are consistently
detected. Data from the PowerQuant1 System provide actionable
information related to the DNA quality and subsequent analysis of
a forensic DNA sample.
2. Materials and methods
2.1. Spectral calibration
The concentrations of the PowerQuant1 Calibration Standards
(i.e. system dyes) provided in the PowerQuant1 Calibration Kit are
100X. The PowerQuant1 Calibration Standards were diluted to 1X
or 2X with the PowerQuant1 Calibration Buffer to prepare the
system dye calibration plates used to calibrate the Applied
Biosystems1 7500 Real-Time PCR System (Thermo Fisher Scien-
tiﬁc, Waltham, MA) [16].
2.2. DNA standard curves
For all studies, serial 25-fold dilutions of the PowerQuant1
Male gDNA Standard were ampliﬁed in duplicate to create four-
point standard curves for the autosomal, Yand degradation targets.
The standard curves were used to estimate a sample’s DNAconcentration based on the results of each target as described in
the PowerQuant1 System Technical Manual [16]. The DNA concen-
trations in the standard curves were 50 ng/mL, 2 ng/mL, 0.08 ng/mL
and 0.0032 ng/mL.
2.3. PowerQuant1 Ampliﬁcation Reactions
The PowerQuant1 20X Primer/Probe/IPC Mix and the Power-
Quant1 2X Master Mix were optimized for the best possible
performance. For the majority of the studies, the PowerQuant1
System reactions contained 7 mL of Water, Ampliﬁcation Grade,
10 mL of PowerQuant1 2X Master Mix, 1 mL of PowerQuant1 20X
Primer/Probe/IPC Mix and 2 mL of DNA template (or water for
negative controls) for a ﬁnal reaction volume of 20 mL. Studies that
used a different ampliﬁcation reaction mix were noted in this
section.
As part of the studies examining PCR-based procedures,
experiments were conducted to evaluate the effect ﬂuctuations
in the concentration of primer mix or master mix had on
ampliﬁcation performance (e.g. pipetting error). Variable amounts
of the PowerQuant1 20X Primer/Probe/IPC Mix or the Power-
Quant1 2X Master Mix were added to the ampliﬁcation reaction to
evaluate the effects on ampliﬁcation and detection. The ﬁnal
concentrations of the PowerQuant1 20X Primer/Probe/IPC Mix or
the PowerQuant1 2X Master Mix for these studies were 0.8X, 0.9X,
1.0X, 1.1X and 1.2X. The volume of Water, Ampliﬁcation Grade was
adjusted to accommodate changes in the volume of the primer mix
or master mix in the ampliﬁcation reaction.
The SwabSolutionTM Kit (Promega Corporation) was designed
for rapid DNA extraction from buccal swabs prior to ampliﬁcation
with a PowerPlex1 System. As part of the stability study, the
compatibility of the SwabSolutionTM Kit with the PowerQuant1
System was tested at one laboratory with eight replicates of 1 ng/
mL male genomic DNA with different volumes of heat inactivated
SwabSolutionTM Reagent. The SwabSolutionTM Reagent was
incubated at 70 C for 30 min as described in the SwabSolutionTM
Kit Technical Manual [17]. The volumes of SwabSolutionTM Reagent
(0, 1, 2, 3, 4, or 5 mL) replaced the equivalent volume of Water,
Ampliﬁcation Grade in the PowerQuant1 System ampliﬁcation
reaction.
2.4. DNA samples
The DNA concentrations (based on A260) and the number of
replicates for each study were indicated in Section 3. For the
majority of the studies, human DNA samples were puriﬁed with
phenol:chloroform; the exceptions were noted in this section [18].
Biological material recovered from evidence items in forensic
cases may include DNA from non-human sources. Species
speciﬁcity studies were conducted using puriﬁed DNA from higher
primates, non-primate animals, and common microorganisms.
Species tested included: chimpanzee, gorilla, orangutan, pig, horse,
deer, cat, rabbit, chicken, dog, cow, mouse, rat, Escherichia coli,
Enterococcus faecalis, Saccharomyces cerevisiae, Fusobacterium
nucleatum, Micrococcus luteus, Streptococcus salivarius, Candida
albicans, Streptococcus mitis, Acinetobacter lwofﬁi, Streptococcus
mutans, and Lactobacillus acidophilus. The DNA concentrations of
the primate species samples (private collection) ranged from
0.25 ng/ml to 10 ng/mL. The other non-human DNA samples were
obtained from ATCC (Manassas, VA), Novagen (Madison, WI),
Promega Corporation, and Zyagen (San Diego, CA). The DNA
concentration of the samples from all other animals and micro-
organisms was 10 ng/mL. Each of the species samples was tested in
duplicate.
DNA isolated from oral swabs collected from three different
female individuals and isolated using the DNA IQTM System
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male speciﬁcity [19]. These samples were tested undiluted and
diluted 1:10 in quadruplicate.
The human DNA samples used for the population studies were
isolated from blood samples using a modiﬁed salt out procedure
[20].
Along with human DNA, PCR inhibitors may be present in a
forensic evidentiary sample and could affect STR analysis. To
evaluate the effect of PCR inhibitors on the PowerQuant1 System,
the following common inhibitors were tested: hematin (Sigma,
cat.# H3281; Sigma-Aldrich, St. Louis, MO), humic acid (Sigma–
Aldrich, cat.# 53680), tannic acid (Sigma-Aldrich, cat.# 403040),
and DNA IQTM Lysis Buffer (Promega Corporation). Different
concentrations of the inhibitors were added to 33.3 pg/mL (based
on A260) of a male genomic DNA. The same male DNA sample with
no inhibitor was used as a control. This DNA concentration was
selected to maximize the amount of template with inhibitor
(15 mL) added to a PowerPlex1 Fusion System (Promega
Corporation) ampliﬁcation reaction to achieve the recommended
template mass for a PowerPlex1 Fusion reaction (0.5 ng);
resulting in a ﬁnal inhibitor concentration six times higher in
the PowerPlex1 Fusion reaction than the PowerQuant1 reaction
[21]. The concentrations of tannic acid in the DNA samples were:
0, 333, 668 or 1000 ng/mL. The concentrations of hematin in the
DNA samples were: 0, 1000, 1333 or 1668 mM. The concentrations
of humic acid in the DNA samples were: 0, 250, 500 or 750 ng/mL.
The concentrations of DNA IQTM Lysis Buffer in the DNA samples
were: 0, 0.02X, 0.04X and 0.08X. Each DNA sample was tested in
quadruplicate with the PowerQuant1 System and the Power-
Plex1 Fusion System (N = 4).
To allow for a controlled assessment of the detection of
degraded DNA, a human male genomic DNA sample was exposed
to different amounts of UV-C energy using a Stratalinker 1800
(Stratagene, La Jolla, CA) to produce degraded DNA (no exposure,
50 mJ,100 mJ and 300 mJ). The UV-C degraded samples were tested
in quadruplicate on two different instruments at two different
laboratories (N = 8).
The reproducibility of the PowerQuant1 System was tested
with the National Institute of Standards and Technology (NIST)
Standard Reference Material1 (SRM) 2372 Human DNA Quantita-
tion Standard (Gaithersburg, MD). Three component genomic DNA
samples were provided in SRM 2372. Component A was derived
from a single male donor. Component B was derived from multiple
female donors. Component C was derived from multiple male and
female donors. The conventional single-stranded DNA concen-
trations (ng/mL) reported in the Certiﬁcate of Analysis for Standard
Reference Material1 2372 for components A, B and C were 57,
61 and 59 ng/mL respectively [22]. Each component of the NIST
SRM 2372 was quantiﬁed in duplicate at the concentration
provided and a 1:10 dilution. The samples and dilutions were
tested on four different ampliﬁcation plates on three different
instruments at two different laboratories (N = 8).
DNA was isolated from the majority of the case-type samples
with a phenol:chloroform:isoamyl alcohol extraction method,
including two non-sperm fractions recovered after differential
extraction [23]. DNA was isolated from a baby tooth and a stain
from a piece of cloth with the DNA IQTM System [24].
2.5. Real-time PCR
The developmental validation studies with the PowerQuant1
System were performed using the Applied Biosystems1 7500 Real-
Time PCR System with either Applied Biosystems1 7500 Software,
Version 2.0.6 or HID Real-Time PCR Analysis Software, Version
1.2 as described in the PowerQuant1 System Technical Manual [16].
A two-stage thermal cycling method was used. The ﬁrst stage was a98 C hold for 2 min. The second stage was 39 cycles of 98 C for 15 s
followed by 62 C for 35 s.
The cycling protocol for the PowerQuant1 System was
developed with an annealing temperature of 62 C. Since temper-
atures may vary slightly from cycler to cycler, the annealing
temperature was increased and decreased 2 C from the recom-
mended temperature as part of the studies evaluating PCR-based
procedures to determine the effect this variation had on the overall
performance of the PowerQuant1 System.
2.6. Analysis of PowerQuant1 Data
Data were analyzed with the Applied Biosystems1 7500 Analy-
sis Software 2.0.6 or HID Real-Time PCR Analysis Software, Version
1.2 using analysis settings described in the PowerQuant1 System
Technical Manual. The results were imported into the Power-
Quant1 System Analysis Tool as described in the PowerQuant1
System Technical Manual for additional calculations and analysis
[16].
The calculations for the [Auto]/[Y] ratios and the [Auto]/[D]
ratios were performed with the PowerQuant1 Analysis Tool. The
tool also calculated the difference in IPC Cq values of the sample
and the closest DNA standard; these values were reported as the
IPC Cq Shift [16]. The IPC Cq shift may be used to evaluate the
presence of PCR inhibitors in a DNA sample. Inhibition of the
PowerQuant1 System was deﬁned as a shift 0.3 Cq. This value
was determined experimentally with different concentrations of
inhibitors during product development by evaluating the correla-
tion of ampliﬁcation efﬁciency between the PowerPlex1 Systems
and the PowerQuant1 IPC Cq.
2.7. Normalization and STR ampliﬁcation
Ampliﬁcation and analysis with the PowerPlex1 Fusion System
was performed with samples from some studies to correlate the
PowerQuant1 System results to STR DNA proﬁles. The maximum
template volume (15 mL) of the DNA samples was added to the
PowerPlex1 Fusion ampliﬁcation reactions for the speciﬁcity and
sensitivity studies, as well as the inhibited DNA samples from the
stability studies. The DNA concentrations determined with the
autosomal target of the PowerQuant1 System were used to
normalize the degraded DNA samples to 0.5 ng per PowerPlex1
Fusion ampliﬁcation reaction. Two microliters of each of the
0.25 ng/mL DNA samples containing a mixture of female and male
DNA were added to PowerPlex1 Fusion ampliﬁcation reactions for
a ﬁnal template mass of 0.5 ng. Based on the concentration of DNA
detected with the autosomal target of the PowerQuant1 System,
the majority of the case-type samples were normalized to a ﬁnal
template mass in the range of 0.24–0.76 ng per PowerPlex1 Fusion
ampliﬁcation reaction. The ampliﬁcation reactions were prepared
as described in the PowerPlex1 Fusion System Technical Manual
and ampliﬁed for 30 cycles [21].
A mixed DNA sample with 200 ng/mL female genomic DNA with
1 ng/mL of male genomic DNA based on A260 was ampliﬁed and
analyzed with the PowerPlex1 Y23 System (Promega Corporation).
The average detected concentration of male DNA based on four
replicates tested with the PowerQuant1 System was 1.18  0.05 ng/
mL. Based on the average concentration determined with the
PowerQuant1 System, the male DNA was normalized to 0.029 ng/
mL in order to achieve a 0.5 ng ﬁnal DNA mass in a 25 mL
PowerPlex1 Y23 ampliﬁcation reaction with addition of 17.5 mL
DNA template. The sample was ampliﬁed in quadruplicate as
described in the PowerPlex1 Y23 System Technical Manual and
ampliﬁed for 30 cycles [25].
All samples were ampliﬁed using a GeneAmp1 9700 (Thermo
Fisher Scientiﬁc). One microliter of the PowerPlex1 Fusion System
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Standard 500 (Part # DG152A) and 10 mL of HiDiTM Formamide
(Thermo Fisher Scientiﬁc). One microliter of the PowerPlex1
Y23 System ampliﬁcation product was added to 1 mL of
CC5 Internal Lane Standard 500 Y23 (Part # DG380A) and 10 mL
of HiDiTM Formamide (Thermo Fisher Scientiﬁc). Electrophoresis
and detection were performed using an Applied Biosystems1
3500xL instrument (Thermo Fisher Scientiﬁc) with a 1.2 kV, 24 s
injection or an Applied Biosystems1 3130xl instrument (Thermo
Fisher Scientiﬁc) with a 3 kV, 5 s injection. Except where noted,
electrophoresis data from an Applied Biosystems1 3500xL
instrument were analyzed with Applied Biosystems1 Gen-
eMapper1 ID-X using a 175rfu analysis threshold. Electrophoresis
data from an Applied Biosystems1 3130xl instrument were
analyzed with Applied Biosystems1 GeneMapper1 ID-X (Thermo
Fisher Scientiﬁc) using a 50rfu analysis threshold.
3. Results and discussion
3.1. Species speciﬁcity
DNA was detected in all of the higher primate DNA samples
(Supplemental Table 1). The higher primate DNA samples were not
ampliﬁed with an STR system because cross-reactivity was
expected. Ampliﬁcation was not detected with any of the
quantiﬁcation targets for all of the non-primate samples, except
for the chicken (0.4 pg/mL with the autosomal target and 0.3 pg/mL
with the degradation target) and the S. salivarius sample (0.1 pg/mL
with the autosomal target). The chicken and the S. salivarius DNA
samples were ampliﬁed in quadruplicate with the PowerPlex1
Fusion System to determine whether human DNA was present in
these samples. Both samples generated ampliﬁcation products in
all replicates consistent with the low-level human DNA contami-
nation detected with the PowerQuant1 System (data not shown).
New sources of the chicken and S. salivarius DNA were purchased
and tested with the PowerQuant1 System. No ampliﬁcation was
detected in the replicates of the new samples conﬁrming the
original samples were contaminated with human DNA rather than
species cross-reactivity in the PowerQuant1 System (data not
shown).
3.2. Male speciﬁcity
Mixtures of male and female DNA are commonly encountered
in forensic DNA analysis. To ensure that the PowerQuant1 System
reliably and speciﬁcally detects male DNA, the system was tested
with different concentrations of single source female genomic
DNA. This sample was tested with DNA concentrations determinedFig. 1. A total of 253 human DNA samples from three different populations were teste
number and grouped by population: African American, Caucasian and Hispanic.by A260 of 200 ng/mL, 150 ng/mL, 100 ng/mL and 50 ng/mL; no
reactivity with the Y chromosomal target was detected in any of
four replicates at each DNA concentration (data not shown).
Autosomal DNA concentrations detected from the samples
collected from female individuals with DNA isolated using the
DNA IQTM System ranged from 26 ng/mL to 1 ng/mL (data not
shown) and no male DNA was detected in any of the replicates
demonstrating male speciﬁcity of the Y chromosomal target.
3.3. Population study
Multicopy targets present in high copy number improve assay
sensitivity. However, the number of copies of these targets may
vary from individual to individual [2,26]. To evaluate the variation
of the multicopy targets in the PowerQuant1 System, individual
human DNA samples from three different male populations:
African American (N = 85), Caucasian (N = 83), and Hispanic
(N = 85) were tested at the National Institute of Standards and
Technology to evaluate the variation in the DNA concentration
detected with the autosomal target relative to the Y chromosomal
target ([Auto]/[Y] ratio) as well as the degradation target ([Auto]/
[D] ratio).
[Auto]/[Y] ratios were calculated for all of the samples. Data
from all three populations were combined and plotted (Fig. 1). The
average [Auto]/[Y] ratio was 1.06  0.14 (N = 253). The coefﬁcient of
variation was 13.3%. The lowest [Auto]/[Y] ratio was 0.53 and the
highest ratio was 1.83.
[Auto]/[D] ratios were calculated for all of the samples. Data
from all three populations were combined and plotted (Supple-
mental Fig. 1). The average [Auto]/[D] ratio was 1.16  0.15
(N = 253). The coefﬁcient of variation was 12.8%. The lowest
[Auto]/[D] ratio was 0.70 and the highest ratio was 1.60.
3.4. Dynamic range and sensitivity
A male genomic DNA sample was serially diluted to different
concentrations based on A260 (100, 50, 10, 2, 0.4, 0.08, 0.016, and
0.0032 ng/mL) to evaluate the dynamic range of the PowerQuant1
System. Each DNA concentration was tested in quadruplicate at
two different laboratories on three different instruments (N = 12)
(Table 1). The highest percentage difference for all three targets
was observed with the 100 ng/mL DNA sample.
Additionally, the sensitivity of the assay was tested with two
different male genomic DNA samples serially diluted to the
following concentrations: 1 pg/mL, 0.5 pg/mL, 0.25 pg/mL, 0.125 pg/
mL, and 0.0625 pg/mL. Each DNA concentration was tested in
quadruplicate at two different laboratories on three different
instruments (N = 12). The number of replicates with DNA detectedd with the PowerQuant1 System. The [Auto]/[Y] ratio was plotted against sample
Table 1
The average DNA concentration and standard deviations detected with the autosomal, Y, and degradation targets (N = 12), as well as the percentage difference between the
average DNA concentration detected with each PowerQuant1 System target and the DNA concentration based on A260.
Sample Concentration Based on
A260 (ng/mL)
[Autosomal]
Average (ng/mL)
[Autosomal]
Percentage Difference
[Y]
Average (ng/mL)
[Y] Percentage
Difference
[Degradation]
Average (ng/mL)
[Degradation] Percentage
Difference
0.0032 0.0026  0.0004 19% 0.0032  0.0009 1.4% 0.0024  0.0005 28%
0.016 0.014  0.002 14% 0.016  0.003 2.0% 0.012  0.002 29%
0.08 0.066  0.009 18% 0.083  0.008 3.9% 0.066  0.003 19%
0.4 0.35  0.04 13% 0.42  0.04 5.0% 0.34  0.03 16%
2 1.7  0.2 16% 2.1  0.1 4.9% 1.7  0.1 16%
10 7.7  0.6 26% 9.6  0.5 4.3% 7.9  0.8 24%
50 37  4 31% 48  6 4.4% 40  5 22%
100 70  4 35% 88  4 13% 73  3 31%
Table 2
The number of replicates with DNA detected are displayed for the PowerQuant1 System targets and DNA concentrations tested. An asterisk (*) was used to denote only three
replicates were included for the 1 pg/mL Male 1 sample because at two loci, three alleles were detected; one allele at each of these loci was not consistent with the known
proﬁle.
Male 1 DNA concentration PowerQuant1 System PowerPlex1 Fusion System
Autosomal (N = 12) Degradation (N = 12) Y (N = 12) Total template mass (pg) Average% alleles detected (N = 4)
1 pg/mL 12 12 12 15 75  9*
0.5 pg/mL 12 11 11 7.5 41  4
0.25 pg/mL 8 6 8 3.8 22  7
0.125 pg/mL 3 2 2 1.9 4.0  3
0.0625 pg/mL 3 0 3 0.94 3.0  3
Male 2 DNA concentration PowerQuant1 System PowerPlex1 Fusion System
Autosomal (N = 12) Degradation (N = 12) Y (N = 12) Total template mass (pg) Average% alleles detected (N = 4)
1 pg/mL 12 12 12 15 68  1
0.5 pg/mL 12 10 12 7.5 36  4
0.25 pg/mL 11 6 7 3.8 23  9
0.125 pg/mL 3 3 3 1.9 7.6  3
0.0625 pg/mL 2 0 0 0.94 7.0  2
No template control PowerQuant1 System PowerPlex1 Fusion System
Autosomal (N = 24) Degradation (N = 24) Y (N = 24) Total template mass (pg) Average% alleles detected (N = 4)
1 1 1 0 0
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PowerQuant1 System consistently detected 0.5 pg/mL with the
autosomal target. DNA was detected in one of the twenty-four
negative control replicates. The DNA concentration determined
with the autosomal target for that replicate was 0.5 pg/mL,Fig. 2. Titration of four different concentrations of tannic acid in a DNA sample with 33
replicates are displayed. Samples with an IPC Cq shift >0.3 Cq or [Auto]/[D] ratios >2 ar
added to a PowerPlex1 Fusion System reaction. Ampliﬁcation reactions were performed
instrument using a 1.2 kV, 24 s injection. Representative electropherograms for each cosuggesting low-level DNA contamination. At the DNA concen-
trations tested, the number of alleles detected varied between
replicates. A partial STR proﬁle was detected for each of the
replicates of the 0.5 pg/mL male DNA samples (Supplemental.3 pg/mL of male DNA. The average IPC Cq shift and the standard deviation for four
e highlighted. Fifteen microliters of each DNA sample mixed with tannic acid were
 using a GeneAmp1 9700 and 1 mL of each sample was electrophoresed on a 3500xL
ncentration of inhibitor are displayed.
Fig. 3. PowerPlex1 Fusion System ampliﬁcation reactions with corresponding UV-C exposure and the average [Auto]/[D] ratios determined with the PowerQuant1 System
and standard deviations (N = 8). Samples with an [Auto]/[D]ratio >2 or an [Auto]/[Y] ratio  2 are highlighted. The PowerPlex1 Fusion ampliﬁcation reactions contained 0.5 ng
of DNA exposed to increasing amounts of UV-C radiation and were performed using the GeneAmp1 PCR System 9700. One microliter of each ampliﬁed sample was
electrophoresed on an Applied Biosystems1 3130xl instrument using a 3 kV, 5 s injection.
Table 3
The average DNA concentration (ng/mL) and coefﬁcient of variation (CV) detected with each of the targets in the PowerQuant1 System for three different DNA
concentrations tested on three different instruments. The number of replicates tested on each instrument are indicated in the table.
DNA Concentration and Run # Average [Autosomal]
(ng/mL)
[Autosomal] CV Average [Degradation]
(ng/mL)
[Degradation] CV Average [Y]
(ng/mL)
[Y] CV
40 ng/mL DD302 Instrument #1 (N = 8) 39  2 6.2% 40  1 3.2% 38  1 2.6%
40 ng/mL DD302 Instrument #2 (N = 8) 39  2 4.4% 42  2 5.1% 40  2 4.8%
40 ng/mL DD302 Instrument #3 (N = 3) 43  3 7.2% 38  4 10% 35  3 9.4%
2 ng/mL DD302 Instrument #1 (N = 7) 2.1  0.2 7.5% 2.1  0.1 4.4% 1.8  0.1 3.2%
2 ng/mL DD302 Instrument #2 (N = 8) 2.0  0.1 6.0% 2.0  0.1 7.0% 1.9  0.1 4.5%
2 ng/mL DD302 Instrument #3 (N = 3) 2.1  0.4 18% 1.9  0.4 21% 1.9  0.3 15%
0.1 ng/mL DD302 Instrument #1 (N = 8) 0.13  0.01 11% 0.11  0.01 7.2% 0.092 0.007 7.2%
0.1 ng/mL DD302 Instrument #2 (N = 8) 0.11  0.01 5.5% 0.10  0.01 7.8% 0.10  0.00 5.2%
0.1 ng/mL DD302 Instrument #3 (N = 3) 0.098  0.011 11% 0.092  0.013 14% 0.096  0.017 18%
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the 0.0625 pg/mL male DNA samples (Supplemental Fig. 3).
3.5. Stability studies
3.5.1. Inhibitors
The same non-degraded DNA sample was used for all inhibited
samples; the condition of the DNA was conﬁrmed with the [Auto]/
[D] ratios and the STR proﬁles obtained from the non-inhibited
sample. A gradual increase in the IPC Cq shift was observed with
increasing tannic acid concentration (Fig. 2). The [Auto]/[D] ratio
also increased gradually with the tannic acid concentration.
However, the IPC Cq shift indicated inhibition at a lower
concentration of tannic acid than the concentration of tannic
acid that increased the [Auto]/[D] ratio greater than the value ofTable 4
The average percentage error determined with the PowerQuant1 System based on the 50
different DNA concentrations tested on three different instruments. The number of rep
DNA Concentration and Run # Percentage Error [Autosomal] 
40 ng/mL DD302 Run #1 (N = 8) 2.8% 
40 ng/mL DD302 Run #2 (N = 8) 1.6% 
40 ng/mL DD302 Run #3 (N = 3) 6.7% 
2 ng/mL DD302 Run #1 (N = 7) 3.7% 
2 ng/mL DD302 Run #2 (N = 8) 0.31% 
2 ng/mL DD302 Run #3 (N = 3) 3.8% 
0.1 ng/mL DD302 Run #1 (N = 8) 27% 
0.1 ng/mL DD302 Run #2 (N = 8) 7.9% 
0.1 ng/mL DD302 Run #3 (N = 3) 2.2% 2.0 typically associated with degraded DNA (Fig. 3). These
observations suggested the high [Auto]/[D] ratio observed with
100 ng/mL of tannic acid was a function of the inhibitor
concentration affecting ampliﬁcation performance of the degra-
dation target rather than the integrity of the DNA. All of the
expected alleles (N = 43) were detected in the PowerPlex1 Fusion
STR proﬁles with no tannic acid or with a ﬁnal concentration of
200 ng/mL tannic acid in the ampliﬁcation reaction. With 400 ng/
mL and 600 ng/mL tannic acid, an average of 42  2 and
38  1 alleles, respectively were detected. However, the signal
intensity of these alleles was low, consistent with an inhibited
STR ampliﬁcation reaction. An IPC Cq shift >0.3 Cq was observed
in the PowerQuant1 System data for all of the concentrations of
tannic acid that affected the PowerPlex1 Fusion System STR
proﬁle. ng/mL concentration supplied for the PowerQuant1Male gDNA Standard for three
licates tested on each instrument are indicated in the table.
Percentage Error [Degradation] Percentage Error [Y]
0.065% 4.2%
4.2% 0.59%
5.2% 12%
3.8% 9.1%
1.3% 6.3%
4.1% 3.5%
12% 8.4%
0.52% 4.9%
7.5% 4.1%
Table 6
The average DNA concentration and IPC Cq results for eight replicates of each component of SRM 2372 at the concentration provided and a 1:10 dilution of each component.
The single-stranded DNA concentrations (ng/mL) for components A, B and C stated in the Certiﬁcate of Analysis for Standard Reference Material1 (SRM) were 57, 61 and 59 ng/
mL respectively. N/A indicates not applicable.
Sample Average [Autosomal]
(ng/mL)
[Autosomal] CV Average [Degradation]
(ng/mL)
[Degradation] CV Average [Y]
(ng/mL)
[Y] CV Average
IPC Cq
IPC CV
NIST SRM 2372 A 51  12 23% 45  9 21% 55  11 20% 21.01  0.29 1.4%
NIST SRM 2372 A diluted 1:10 4.9  1.1 22% 4.6  0.8 17% 5.2  0.8 15% 20.84  0.26 1.3%
NIST SRM 2372 B 57  11 19% 45  10 21% N/A N/A 20.69  0.30 1.4%
NIST SRM 2372 B diluted 1:10 5.5  1.1 20% 4.7  0.8 17% N/A N/A 20.67  0.28 1.4%
NIST SRM 2372 C 46  6 12% 38  3 6.7% 31  2 5.3% 20.86  0.31 1.5%
NIST SRM 2372C diluted 1:10 4.6 + 0.9 19% 4.0  0.4 10% 3.1  0.3 11% 20.74  0.25 1.2%
Table 5
The intra-run and inter-run average DNA concentration (ng/mL) and coefﬁcient of variation (CV) detected with each of the targets in the PowerQuant1 System for a 1 ng/mL
human male DNA sample. The number of replicates for each run are indicated in the table. Runs #1 through #3 were performed on one instrument; runs #4 and #5 were
performed on a different instrument.
Run Average [Autosomal]
(ng/mL)
[Autosomal] CV Average [Degradation]
(ng/mL)
[Degradation] CV Average [Y]
(ng/mL)
[Y] CV Average
IPC Cq
IPC Cq CV
Run #1 (N = 8) 0.99  0.13 14% 0.88  0.04 5.0% 1.0  0.0 3.3% 20.48  0.11 0.53%
Run #2 (N = 8) 1.0 + 0.1 11% 1.0  0.1 5.2% 1.1  0.1 7.2% 20.93  0.20 0.93%
Run #3 (N = 8) 0.74 + 0.08 11% 0.72  0.03 4.3% 0.83  0.04 4.9% 20.70  0.09 0.42%
Run #4 (N = 8) 0.80 + 0.06 7.4% 0.82  0.06 6.9% 0.99  0.03 2.6% 21.07  0.11 0.51%
Run #5 (N = 8) 0.93 + 0.03 3.4% 0.81  0.05 6.7% 1.0  0.0 4.7% 20.85  0.10 0.50%
Inter-run (N = 40) 0.90  0.14 16% 0.85  0.11 12% 0.98  0.09 10% 20.80  0.24 1.1%
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increasing hematin concentration (Supplemental Fig. 4). None of
the [Auto]/[D] ratios exceeded the value 2.0. All of the expected
alleles (N = 43) were detected in the STR proﬁles with no hematin
or a ﬁnal concentration of 600 mM hematin in the PowerPlex1
Fusion ampliﬁcation reaction; although the average peak height
detected was lower in the STR proﬁles with 600 mM hematin. With
800 mM hematin in the PowerPlex1 Fusion reaction, an average of
37  7 alleles were detected with allelic dropout observed atFig. 4. The ratio of female DNA to male genomic DNA based on concentrations determi
System (secondary vertical axis). The percentage of alleles unique to the male contribu
each ratio are displayed on the primary vertical axis. The PowerPlex1 Fusion ampliﬁca
System 9700. One microliter of each ampliﬁed sample was electrophoresed on an ApAmelogenin, Penta D and Penta E. An average of 16  7 alleles were
detected with the PowerPlex1 Fusion reaction with 1000 mM
hematin. An IPC Cq shift >0.3 Cq was observed in the PowerQuant1
System data for all of the concentrations of hematin that affected
the PowerPlex1 Fusion System STR proﬁle.
A gradual increase in the IPC Cq shift was observed with
increasing humic acid concentration (Supplemental Fig. 5). All of
the [Auto]/[D] ratios were less than the value 2.0. All of the
expected alleles (N = 43) were detected in the STR proﬁles with noned with A260 was plotted against the [Auto]/[Y] ratio detected with the PowerQuant1
tor detected after ampliﬁcation and analysis with the PowerPlex1 Fusion System for
tion reactions contained 0.5 ng of DNA and were performed using the GeneAmp1 PCR
plied Biosystems1 3500xL instrument using a 1.2 kV, 24 s injection.
Fig. 5. The average DNA concentration detected with the autosomal target for the PowerQuant1 System was plotted on the primary vertical axis against the [Auto]/[Y] ratio
based on A260. The average DNA concentration detected with the Y chromosomal target for the PowerQuant1 System was plotted on the secondary vertical axis.
M.M. Ewing et al. / Forensic Science International: Genetics 23 (2016) 166–177 173humic acid or a ﬁnal concentration of 150 ng/mL humic acid in the
PowerPlex1 Fusion ampliﬁcation reaction. With 300 ng/mL humic
acid in the PowerPlex1 Fusion reaction, an average of 18  0 alleles
were detected. With 450 ng/mL humic acid in the PowerPlex1
Fusion reaction, one allele was detected at the TH01 locus in oneTable 7
Summary of the [Auto]/[Y], [Auto]/[D], IPC and STR data for thirteen case-type samplereplicate. An IPC Cq shift >0.3 Cq was observed in the PowerQuant1
System data for all of the concentrations of humic acid that affected
the PowerPlex1 Fusion System STR proﬁle.
An IPC Cq shift was observed with 0.004X DNA IQTM Lysis Buffer
in the PowerQuant1 ampliﬁcation reaction (Supplemental Fig. 6).s. Samples with an [Auto]/[Y] ratio > 2 or an [Auto]/[D] ratio >2 are highlighted.
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0.008X DNA IQTM Lysis Buffer in the PowerQuant1 ampliﬁcation
reaction. The IPC Cq shift indicated inhibition at a lower
concentration of DNA IQTM Lysis Buffer than the concentration
that caused ampliﬁcation failure of the degradation target. All
expected alleles (N = 43) were detected in the STR proﬁles with no
DNA IQTM Lysis Buffer in the PowerPlex1 Fusion ampliﬁcation
reaction. With 0.012X DNA IQTM Lysis Buffer in the PowerPlex1
Fusion reaction, an average of 40  0.5 alleles were detected with
dropout occurring at the Penta E and Penta D loci. No alleles were
detected with 0.024X or 0.048X DNA IQTM Lysis Buffer added to the
PowerPlex1 Fusion ampliﬁcation reaction.
3.5.2. Degraded DNA
The [Auto]/[Y] and [Auto]/[D] ratios for each amount of UV-C
exposure were calculated. These DNA samples were also ampliﬁed
with the PowerPlex1 Fusion System in order to correlate the
[Auto]/[D] ratio to an STR proﬁle. As the UV-C exposure increased,
the [Auto]/[D] ratios also increased. The [Auto]/[Y] ratio gradually
increased with UV-C exposure, demonstrating the [Auto]/[Y] ratio
was minimally affected until the DNA was severely degraded. DNA
exposure to UV-C did not affect the IPC Cq. The higher [Auto]/[D]
ratios corresponded to STR proﬁles exhibiting characteristics of
degraded DNA (Fig. 3).
3.5.3. SwabSolutionTM Kit
No signiﬁcant effects on the IPC or the quantiﬁcation results for
each target were observed with any of the volumes of SwabSo-
lutionTM Reagent tested (data not shown).
3.6. Precision and accuracy
3.6.1. Precision
To evaluate the precision of the PowerQuant1 System, the
PowerQuant1 Male gDNA Standard (Part # DD302) was serially
diluted to concentrations within the linear range of the standard
curve based on the 50 ng/mL concentration provided. The
concentrations tested were 40, 2 and 0.1 ng/mL (based on the
starting concentration). Replicates of each concentration were
quantiﬁed on three different instruments at two different
laboratories. The number of replicates for each DNA concentration,
the average DNA concentration determined for each target, and the
coefﬁcient of variation (CV) are displayed in Table 3.
3.6.2. Accuracy
The samples used for the precision study were also used to
evaluate the accuracy of the PowerQuant1 System. The percentage
error was determined based on the expected concentrations of the
PowerQuant1 Male gDNA Standards and the measured concen-
trations with the PowerQuant1 System. The number of replicates
for each DNA concentration and the percentage error for each
target are displayed in Table 4. In general, the percentage error was
fairly low. Higher percentage error was observed in some replicates
of the 0.1 ng/mL samples which was consistent with expectations
for samples with lower DNA concentration.
3.6.3. Repeatability
To evaluate the repeatability of the PowerQuant1 System, a
human male genomic DNA sample was diluted to 1 ng/mL (A260)
and eight replicates of the sample were quantiﬁed with ﬁve
different PowerQuant1 runs on two different instruments. The
intra-run and inter-run average DNA concentration detected and
the CV for each target are shown in Table 5. The average IPC Cq and
the coefﬁcient of variation are also shown. In general, the intra-run
CV was less than 15% and the inter-run CV was 16% or less.Ta A di
M.M. Ewing et al. / Forensic Science International: Genetics 23 (2016) 166–177 1753.6.4. Reproducibility
The NIST SRM 2372 components were tested on four different
ampliﬁcation plates on three different instruments at two different
laboratories (N = 8). The inter-run average DNA concentration
detected and coefﬁcient of variation for each target are displayed in
Table 6. The average IPC Cq and the coefﬁcient of variation are also
shown. In general, the CV was less than 23% for the quantiﬁcation
targets.
3.7. Mixture studies
The ability to detect mixtures of male and female DNA with a
quantiﬁcation system, reliably providing a ratio of total human to
total human male DNA, allows a forensic DNA analyst to use that
information to guide the selection of an STR system that will result
in the most useful DNA proﬁle for that sample (e.g. autosomal STRs
or Y-STRs). Detection of mixtures of male and female DNA with the
PowerQuant1 System was tested with three different mixture sets
prepared from male and female genomic DNA.
The total DNA concentration of the ﬁrst mixture set was 0.25 ng/
mL with female DNA to male DNA ratios of 30:1, 20:1, 10:1, 5:1,
2:1 and 1:1. All of the samples in this mixture set were tested in
quadruplicate on three different instruments at two different
laboratories (N = 12) and the [Auto]/[Y] ratio was plotted against
the female DNA to male DNA ratio (secondary vertical axis in
Fig. 4). To correlate the mixture ratios with STR proﬁles, the
samples were ampliﬁed and analyzed with the PowerPlex1 Fusion
System. The number of alleles unique to the male contributor were
counted and the percentage of alleles unique to the male
contributor was determined (primary vertical axis in Fig. 4).
The second mixture set included a constant male DNA
concentration of 1 pg/mL (based on A260) with increasing concen-
trations of female DNA (0, 50, 100 or 200 ng/mL based on A260).
Data shown in Fig. 5 were from four replicates run on one
instrument. The autosomal DNA concentration detected with the
PowerQuant1 System increased as the ratio of female DNA to male
DNA increased; however, the amount of male DNA detected with
the Y chromosomal target of the PowerQuant1 System remained
constant at approximately 1 pg/mL. This mixture set demonstrated
that 1 pg/mL of male DNA was reliably detected in a background of
200,000 fold excess of female genomic DNA.
The third mixture set included samples with a constant female
DNA to male DNA ratio of 200:1 while decreasing the total DNA
concentration. This mixture set was prepared with a mixed DNA
sample with 200 ng/mL female genomic DNA and 1 ng/mL male
genomic DNA based on A260. This mixed DNA sample was serially
diluted 10-fold for two additional concentrations: 20 ng/mL female
DNA with 0.1 ng/mL male DNA and 2 ng/mL female DNA with
0.01 ng/mL male DNA. Data shown in Supplemental Fig. 7 were
from four replicates tested on one instrument. This mixture set
demonstrated that the [Auto]/[Y] ratio detected with the Power-
Quant1 System for the mixture sample remained constant as the
total concentration of DNA decreased.
For a sample with a 200:1 ratio of female to male genomic DNA,
Y-STR testing is required for analysis of the male DNA. The averageTable 9
A summary of the average DNA concentration and IPC Cq and standard deviation fo
concentration of the PowerQuant1 20X Primer/Probe/IPC Mix in the ampliﬁcation reac
Final PowerQuant1 20X Primer/Probe/IPC Mix Concentration [Autosom
0.8X 0.92  0
0.9X 0.84  0
1.0X 0.97  0
1.1X 1.1  0
1.2X 1.0  0concentration of male DNA detected with the Y target of the mixed
DNA sample with 200 ng/ml female genomic DNA and 1 ng/mL
male genomic DNA was 1.18  0.05 ng/mL. This concentration was
used to normalize the male DNA to 0.029 ng/mL for ampliﬁcation of
500 pg of template (based on 17.5 mL addition to the ampliﬁcation
reaction) with the PowerPlex1 Y23 System. A complete Y-STR
proﬁle was detected with peak heights in the expected rfu range
demonstrating the concentration of male DNA detected is reliable
for normalizing male DNA prior to Y-STR analysis (Supplemental
Fig. 8).
3.8. Case-type samples
A total of thirteen non-probative and mock casework samples
were tested with the PowerQuant1 System and the PowerPlex1
Fusion System in the Madison and Milwaukee laboratories in the
Wisconsin State Crime Laboratory Bureau. Four touched items,
three bloodstains, a reference sample collected in 2001, a cigarette
butt, one baby tooth, and three male/female mixed DNA samples
were quantiﬁed with the PowerQuant1 System and ampliﬁed for
autosomal STRs with the PowerPlex1 Fusion System. An [Auto]/[Y]
ratio greater than two was used to indicate that a sample was a
mixture of female and male DNA. An [Auto]/[D] ratio greater than
two was used to indicate a DNA sample was degraded. The samples
were also evaluated for the presence of PCR inhibitors with the
PowerQuant1 System IPC. An IPC shift greater than 0.3 Cq was used
to indicate inhibition; however, differential ampliﬁcation of loci
consistent with inhibition was not observed in any of the STR
proﬁles. An STR proﬁle was considered a mixture if three or more
alleles were detected at more than one locus. An STR proﬁle was
considered degraded if the rfu values of the smaller loci were at
least two times greater than the rfu values at the larger loci
(sloped). The correlation of the [Auto]/[Y] ratios, [Auto]/[D] ratios,
and IPC Cq shift to the STR proﬁles were evaluated and are
displayed in Table 7.
The STR proﬁle detected from the cigarette butt was consistent
with a single source female contributor (data not shown). A male
contributor (0.008 ng/mL) was detected with the Y chromosomal
target of the PowerQuant1 System with an [Auto]/[Y] ratio of
287.13 (Table 7). Failure to detect a male contributor with an
autosomal STR system was consistent with the [Auto]/[Y] ratio.
The concentration of DNA detected from the cutting of a leaf
with a bloodstain was 1.8 pg/mL. Addition of the maximum amount
of this DNA sample (27 pg) to a PowerPlex1 Fusion ampliﬁcation
reaction resulted in a partial proﬁle (locus drop-out at Penta E and
DYS391) with low peak heights (data not shown). Three alleles
were detected at the D16S539 locus. The PowerQuant1 System did
not detect a mixture of male and female DNA (Table 7).
The PowerPlex1 Fusion System generated a proﬁle consistent
with a least two contributors (major female, minor male) from the
non-sperm fraction of a semen-positive bloodstain in a pair of
underwear. The only indications of male DNA in the STR proﬁle
were the Y allele at Amelogenin and the allele detected at DYS391
(Supplemental Fig. 9). The [Auto]/[Y] ratio detected with the
PowerQuant1 System was 22.11 while the [Auto]/[D] ratio wasr four replicates of a 1 ng/mL (A260) male DNA sample detected with each ﬁnal
tion.
al] [Degradation] [Y] IPC Cq
.05 0.81  0.05 0.97  0.05 20.39  0.06
.05 0.75  0.07 0.93  0.05 20.39  0.22
.10 0.88  0.06 1.1  0.0 20.52  0.04
.0 0.93  0.07 1.2  0.0 20.73  0.05
.0 1.0  0.1 1.2  0.0 20.93  0.05
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degradation (Table 7).
3.9. PCR-based procedures
3.9.1. Annealing temperature
Performance with different annealing temperatures was tested
with duplicate standard curves, quadruplicate negative controls,
and duplicates of the following extracted DNA samples on two
different instruments at one laboratory: female DNA (205 and
50 ng/mL); male DNA (1 and 0.001 ng/mL); and a mixed DNA
sample with 1 pg/mL male contributor and 100 ng/mL female
contributor. At all annealing temperatures, the standard curve
parameters were within the expected ranges described in the
PowerQuant1 System Technical Manual (Supplemental Table 2)
[16]. For all annealing temperatures tested, no quantiﬁcation
values were detected with any of the targets in the negative
controls. No changes in speciﬁcity of the Y target were observed in
any of the female DNA samples with either 60 C or 64 C annealing
temperature. No differences in sensitivity of any of the quantiﬁca-
tion targets were observed when the annealing temperature was
altered by 2 C in either direction (data not shown).
3.9.2. PowerQuant1 20X Primer/Probe/IPC Mix concentration
A male DNA sample (1 ng/mL determined with A260) was
quantiﬁed in quadruplicate with each reaction mix. Changes in the
ﬁnal concentration of the PowerQuant1 20X Primer/Probe/IPC Mix
did not have any signiﬁcant effect on the standard curves or the
quantiﬁcation of the male DNA sample (Tables 8 and 9).
3.9.3. PowerQuant1 2X master Mix concentration
A male DNA sample (1 ng/mL determined with A260) was
quantiﬁed in quadruplicate with each reaction mix. Changes in the
ﬁnal concentration of the PowerQuant1 2X Master Mix did not
have any signiﬁcant effect on the standard curves or the
quantiﬁcation of the male DNA sample, although a later IPC Cq
value was observed with 1.2X ﬁnal concentration of the Power-
Quant1 2X Master Mix (Tables 10 and 11). This corresponds to a
12 mL addition of 2X Master Mix per 20 mL ampliﬁcation reaction
rather than the recommended 10 mL. The observed effect on the
IPC can likely be attributed to the higher cation concentration
reducing ampliﬁcation efﬁciency of the 435 bp IPC amplicon. This
effect was consistent with data generated during product
development with titration of individual master mix components.
4. Conclusions
The PowerQuant1 System was designed not only to provide
total human and total human male DNA concentrations in a DNA
sample extracted from a forensic evidence item, but also data
about the condition of the DNA sample. The additional data
obtained at quantiﬁcation may be used by the analyst to determine
the most effective procedure for processing the sample for STR
analysis. The experiments presented in this paper verify the
PowerQuant1 System is a robust method producing reliable and
reproducible results and address the SWGDM Validation Guide-
lines for evaluating a new methodology. The results of the
experiments completed at the collaborating laboratories demon-
strate that the DNA concentrations determined with the Power-
Quant1 System may be used to normalize DNA samples for STR
ampliﬁcation. The system routinely detects DNA at concentrations
too low to yield interpretable STR proﬁles. Low levels of male DNA
were detected in samples with high concentrations of female DNA.
Since the IPC amplicon has greater sensitivity to PCR inhibitors
than the degradation amplicon, a sample with an [Auto]/[D] ratio
greater than two and no observed IPC Cq shift likely contains
Table 11
A summary of the average DNA concentration and IPC Cq and standard deviation for four replicates of a 1 ng/mL (A260) male DNA sample detected with each ﬁnal
concentration of the PowerQuant1 2X Master Mix in the ampliﬁcation reaction. One replicate of the IPC failed to cross the detection threshold with a 1.2X ﬁnal concentration.
Data for that sample are indicated with an * (N = 3).
Final PowerQuant1 2X Master Mix Concentration [Autosomal] [Degradation] [Y] IPC Cq
0.8X 0.84  0.10 0.78  0.03 0.94  0.04 20.29  0.07
0.9X 0.81  0.08 0.78  0.02 0.94  0.04 20.38  0.13
1.0X 0.94  0.05 0.82  0.07 1.1  0.1 20.64  0.15
1.1X 1.1  0.1 0.92  0.10 1.2  0.1 21.02  0.21
1.2X 1.0  0.1 0.86  0.10 1.2  0.1 31.47  16.71*
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the PowerQuant1 reaction, no instances of an [Auto]/[D] ratio
greater than two were observed without a shift in the IPC Cq,
preventing the false identiﬁcation of a degraded DNA sample due
to PCR inhibition. Additionally, the PowerQuant1 System provides
an analyst data to assess the presence of PCR inhibitors and DNA
degradation that could affect the corresponding STR proﬁles
making it a useful tool for evaluating the quality of an extracted
DNA sample.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
fsigen.2016.04.007.
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